Syndecan-4 Peptide Segment Inhibits Integrin EGFR Interaction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective targeting mechanisms for the tumor-promoting activities of the α6β4 integrin, which is involved in cancer cell invasion, metastasis, and angiogenesis, particularly in cancers like breast and head and neck squamous cell carcinomas, where it interacts with EGFR and syndecan-4.
Innovation Solution
A peptide segment comprising residues 87-131 of syndecan-4 is used to inhibit the interaction between α6β4 integrin and EGFR, disrupting the signaling that drives tumor growth and survival, and is administered to cancer cells or as a therapeutic agent to block tumor-induced angiogenesis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used to treat cancer, then general cancer treatment is provided, but they lack effective targeting mechanisms for tumor-promoting activities of α6β4 integrin
Solution Approach 1:
The invention segments the syndecan-4 molecule to identify and utilize a specific peptide segment (residues 87-131) that mediates the interaction between α6β4 integrin and EGFR. This segmentation allows targeted inhibition of the tumor-promoting interaction without affecting other functions of the complete syndecan-4 molecule or unrelated pathways.
Solution Approach 2:
The peptide segment derived from syndecan-4 acts as an intermediary that specifically blocks the interaction between α6β4 integrin and EGFR. By introducing this peptide as a mediator, the invention prevents the harmful signaling complex formation while maintaining the natural biological context, providing selective targeting without requiring complete pathway disruption.
2Object-affected harmful factors
If α6β4 integrin is targeted to inhibit tumor growth, then tumor cell proliferation and invasion are reduced, but the complexity of identifying and targeting the specific integrin-EGFR-syndecan interaction increases
Solution Approach 1:
The invention extracts the critical functional segment (residues 87-131) from the complete syndecan-4 molecule that is responsible for mediating the α6β4 integrin-EGFR interaction. This extracted peptide segment can be produced independently and used as a targeted therapeutic agent, simplifying the delivery and application while maintaining specific inhibitory activity against the tumor-promoting pathway.
Solution Approach 2:
The invention creates a simplified copy (peptide segment) of the critical functional region of syndecan-4 that is sufficient to block the pathological interaction. This peptide copy retains the essential binding properties needed to inhibit α6β4 integrin-EGFR association while being much smaller and more manageable than the complete syndecan-4 protein, facilitating therapeutic development and deployment.
Data Source
AI summary
The invention provides for peptides from syndecan 4 and methods of use therefor. These peptides can inhibit α6β4 integrin interaction with EGFR, thereby preventing tumor cell growth and tissue invasion, or inhibiting scarring and/or pathologic neovascularization.